Opinion · 22 Oct 2024
Research articlePublished 2019
Qualitative Analysis of the Biological Testing of Novel Telomerase Inhibitors
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cancer is often referred to as being “immortal” because of high telomerase activity in these cells, which allows them to divide an infinite amount of times. BIBR-1532, (2-{[(2E)-3-(2Naphthyl)-2-butenoyl]amino}benzoic acid) is a known telomerase inhibitor that has undergone preclinical trials for the treatment of cancer. Based on the structure of BIBR-1532, three novel N- cinnamoyl substituted anthranilic acid derivatives (2-{[(2E)-3-(4 “ X ” phenyl)-2- propenoyl]amino}benzoic acids), similar to BIBR-1532 were synthesized. Their efficacies were tested against proliferative activity in metastatic prostate cancer cells, along with the known telomerase inhibitor BIBR-1532. Telomerase Repeat Amplification Protocol (TRAP) assays were performed on the compounds to confirm their antitelomerase activity. The results showed all three newly synthesized cinnamic derivatives have antiproliferative qualities equivalent to or better than BIBR-1532 (p=0.027) and overall all compounds were significantly lower than the control (p<0.0001). TRAP assays further confirmed that the compounds also exhibited anti-telomerase activity like BIBR-1532. The newly synthesized cinnamic acid derivatives of BIBR- 1532 all showed antiproliferative and antitelomerase activity. While these compounds were all tested against metastatic prostate cancer cells, these potential treatments have application in all types of cancers demonstrating high telomerase activity.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in International Journal of Drug Development and Research.
Opinion · 22 Oct 2024
From Monoclonal Antibodies to CAR-T Therapy: Trends and Transformations in Cancer Treatment
Perspective · 21 Oct 2024
Natural Products in Drug Discovery: From Traditional Remedies to Modern Medicines
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Drug Development and Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Suganthi Sridhar”
- BylineArticles whose byline prints “Katie Uhl”
- BylineArticles whose byline prints “Basma Khudur”
- BylineArticles whose byline prints “Bikash Mishra”
- BylineArticles whose byline prints “Robert Smart”
- BylineArticles whose byline prints “William Schroeder”
